Aliases & Classifications for Leukoplakia

MalaCards integrated aliases for Leukoplakia:

Name: Leukoplakia 50 52 69

Classifications:



Summaries for Leukoplakia

NIH Rare Diseases : 50 leukoplakia is a condition in which thickened, white patches form on the tongue, gums, inside of the cheek, or sometimes on the outer female genitals. although the sores can vary in appearance, they are usually white or gray; thick; and slightly raised with a hard surface. the condition is thought to be caused by irritation, but the cause is not always known. tobacco is considered to be the main cause of its development in the mouth. most patches are benign, but a small percentage show early signs of cancer. removing the source of irritation may cause the condition to go away, but surgery to remove the sore(s) may be necessary in some cases. last updated: 5/21/2012

MalaCards based summary : Leukoplakia is related to oral hairy leukoplakia and oral leukoplakia. An important gene associated with Leukoplakia is DKC1 (Dyskerin Pseudouridine Synthase 1), and among its related pathways/superpathways are Keratinization and Acetaminophen Pathway (therapeutic doses), Pharmacokinetics. The drugs Aminolevulinic acid and Dermatologic Agents have been mentioned in the context of this disorder. Affiliated tissues include tongue, bone marrow and bone, and related phenotype is Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435).

Wikipedia : 72 Leukoplakia generally refers to a firmly attached white patch on a mucous membrane which is associated... more...

Related Diseases for Leukoplakia

Diseases related to Leukoplakia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
id Related Disease Score Top Affiliating Genes
1 oral hairy leukoplakia 12.4
2 oral leukoplakia 12.3
3 uterine cervix leukoplakia 12.0
4 leukoplakia of penis 11.9
5 leukoplakia of vagina 11.9
6 esophageal leukoplakia 11.9
7 oral mucosa leukoplakia 11.9
8 dyskeratosis congenita 11.3
9 dyskeratosis congenita, autosomal recessive 5 10.9
10 dyskeratosis congenita, autosomal dominant 2 10.9
11 dyskeratosis congenita, autosomal dominant 3 10.9
12 revesz syndrome 10.9
13 dyskeratosis congenita, autosomal recessive 1 10.9
14 dyskeratosis congenita, autosomal recessive 6 10.9
15 dyskeratosis congenita, autosomal dominant 6 10.9
16 dyskeratosis congenita, autosomal recessive 3 10.9
17 dyskeratosis congenita, x-linked 10.9
18 dyskeratosis congenita, autosomal dominant 1 10.7
19 dyskeratosis congenita, autosomal recessive 2 10.7
20 poikiloderma with neutropenia 10.7
21 mouth disease 10.7
22 asbestos intoxication 10.6 GSTM1 GSTT1
23 squamous cell carcinoma 10.5
24 emery-dreifuss muscular dystrophy, dominant type 10.5 GSTM1 GSTT1
25 hypothyroidism due to deficient transcription factors involved in pituitary development or function 10.5 CYP1A1 GSTM1
26 basedow's coma 10.5 CYP1A1 GSTT1
27 hepatocellular adenoma 10.5 GSTM1 GSTT1
28 mycetoma 10.5 GSTM1 GSTT1
29 gastric adenocarcinoma 10.5 MKI67 PCNA
30 gastrointestinal tularemia 10.4 GSTM1 GSTT1
31 oral squamous cell carcinoma 10.4
32 cervical incompetence 10.4 GSTM1 GSTT1
33 boylan dew greco syndrome 10.4 MKI67 PCNA
34 diffuse mesangial sclerosis 10.4 GSTM1 GSTT1
35 pediatric meningioma 10.4 MKI67 PCNA
36 berylliosis 10.4 GSTM1 GSTT1
37 joint disorders 10.4 GSTM1 GSTT1
38 lichen planus 10.3
39 oral cancer 10.3
40 laryngeal adenoid cystic carcinoma 10.2 MKI67 PCNA
41 hepatic flexure cancer 10.2 GSTM1 GSTT1 MKI67
42 oral submucous fibrosis 10.2
43 oral lichen planus 10.2
44 hypocalciuric hypercalcemia, type i 10.2 DKC1 GSTM1 GSTT1
45 cavernous hemangioma of face 10.2 CYP1A1 GSTM1 GSTT1
46 retroperitoneal sarcoma 10.2 GSTM1 GSTT1
47 measles 10.2 CYP1A1 GSTM1 GSTT1
48 ovarian cystadenocarcinoma 10.2 GSTM1 GSTT1
49 pulmonary fibrosis, idiopathic susceptibility 10.2 CYP1A1 GSTM1 GSTT1
50 candidiasis 10.1

Graphical network of the top 20 diseases related to Leukoplakia:



Diseases related to Leukoplakia

Symptoms & Phenotypes for Leukoplakia

GenomeRNAi Phenotypes related to Leukoplakia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 DKC1 MKI67 PCNA

Drugs & Therapeutics for Leukoplakia

Drugs for Leukoplakia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 3,Phase 1,Phase 2 106-60-5 137
2 Dermatologic Agents Phase 3,Phase 1,Phase 2
3 Photosensitizing Agents Phase 3,Phase 1,Phase 2
4
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
5
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
6
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
7
Ketorolac Approved Phase 2 74103-06-3, 66635-83-4 3826
8
Trioxsalen Approved Phase 2 3902-71-4 5585
9
Metformin Approved Phase 2 657-24-9 14219 4091
10
Maleic acid Experimental Phase 2 110-16-7 444266
11
Fenretinide Investigational Phase 2 65646-68-6
12 Analgesics Phase 2,Phase 1
13 Analgesics, Non-Narcotic Phase 2,Phase 1
14 Anti-Inflammatory Agents Phase 2,Phase 1
15 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1
16 Antirheumatic Agents Phase 2,Phase 1
17 Cyclooxygenase 2 Inhibitors Phase 2
18 Cyclooxygenase Inhibitors Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 2,Phase 1
20 Hypoglycemic Agents Phase 2
21 Retinamide Phase 2
22 Ketorolac Tromethamine Phase 2
23 Pharmaceutical Solutions Phase 1, Phase 2
24 Dihematoporphyrin Ether Phase 2
25 Ether Phase 2
26 Hematoporphyrin Derivative Phase 2
27 Hematoporphyrins Phase 2
28 Tea Nutraceutical Phase 2
29
Aspirin Approved, Vet_approved Phase 1 50-78-2 2244
30 Antipyretics Phase 1
31 Fibrinolytic Agents Phase 1
32 Platelet Aggregation Inhibitors Phase 1
33
Heparin Approved, Investigational 9005-49-6 772 46507594
34
Dapsone Approved, Investigational 80-08-0 2955
35
Nicotine Approved 54-11-5 942 89594
36
Sulindac Approved 38194-50-2 5352 1548887
37
Folic Acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
38
leucovorin Approved, Nutraceutical 58-05-9 143 6006
39 Acyclovir
40 Anti-Infective Agents
41 Antiviral Agents
42 calcium heparin
43 Coagulants
44 Hemostatics
45 Tolonium Chloride
46 Anti-Bacterial Agents
47 Antimalarials
48 Antiparasitic Agents
49 Antiprotozoal Agents
50 Folic Acid Antagonists

Interventional clinical trials:

(show all 35)

id Name Status NCT ID Phase Drugs
1 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
2 Photodynamic Therapy for Oral Precursor Lesions Completed NCT01497951 Phase 3
3 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Unknown status NCT00052611 Phase 2 celecoxib
4 Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia Completed NCT00369174 Phase 2 rosiglitazone maleate
5 Fenretinide in Treating Patients With Leukoplakia of the Mouth Completed NCT00004161 Phase 2 fenretinide;Placebo
6 Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00099021 Phase 2 pioglitazone hydrochloride
7 Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR Completed NCT00001698 Phase 2 Ketorolac Rinse
8 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
9 Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
10 Treatment of Oral Premalignant Lesions With 5-ALA PDT Completed NCT00571974 Phase 1, Phase 2 5-Aminolevulinic Acid (Levulan KerastickTM)
11 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract Completed NCT00453336 Phase 2 Porfimer Sodium
12 Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Active, not recruiting NCT02581137 Phase 2 Metformin Hydrochloride
13 A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia Terminated NCT00176566 Phase 2 Lozenge Intake
14 Pioglitazone for Oral Premalignant Lesions Terminated NCT00951379 Phase 2 Pioglitazone hydrochloride
15 Aspirin Mouthwash in Treating Patients With Oral Leukoplakia Completed NCT01238185 Phase 1 acetylsalicylic acid
16 Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Terminated NCT00571558 Phase 1 aminolevulinic acid hydrochloride;photodynamic therapy
17 Least Invasive Nonlinear Light Microscopy Unknown status NCT00767442
18 Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity Unknown status NCT01636544
19 Comparison Between Two Different High Power Ablative Lasers in the Treatment of Oral Leukoplakia Completed NCT03233165
20 Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV) Completed NCT00002026 Acyclovir
21 Biomarkers for Oral Cancer Completed NCT00341497
22 Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy Completed NCT03031899
23 Natural History of Oro-pharyngeal Cancer Precursors Completed NCT00179361
24 Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC) Completed NCT00002043 Dapsone
25 A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome Completed NCT00862576
26 Clinical Research Core Dental Screening Protocol Completed NCT00090818
27 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia Completed NCT00835341
28 Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions Completed NCT02323672
29 A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery Recruiting NCT01355926
30 Cancer in Inherited Bone Marrow Failure Syndromes Recruiting NCT00027274
31 Tobacco Cessation Intervention Study for Oral Diseases Recruiting NCT02737176
32 Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making Recruiting NCT03239834
33 Fluorescence & Reflectance Imaging to Detect Oral Neoplasia Recruiting NCT00542373
34 International Pachyonychia Congenita Research Registry Recruiting NCT02321423
35 A Randomized Study of Sulindac in Oral Premalignant Lesions Active, not recruiting NCT00299195 sulindac;Placebo

Search NIH Clinical Center for Leukoplakia

Genetic Tests for Leukoplakia

Anatomical Context for Leukoplakia

MalaCards organs/tissues related to Leukoplakia:

39
Tongue, Bone Marrow, Bone, T Cells, Liver, Prostate, Testes

Publications for Leukoplakia

Articles related to Leukoplakia:

(show top 50) (show all 892)
id Title Authors Year
1
Type of surgical treatment and recurrence of oral leukoplakia: A retrospective clinical study. ( 28809365 )
2017
2
New definition proposed for oral leukoplakia. ( 28928786 )
2017
3
PTEN allelic loss is an important mechanism in the late stage of development of oral leukoplakia into oral squamous cell carcinoma. ( 28858374 )
2017
4
Oral leukoplakia and oral cavity squamous cell carcinoma. ( 28916027 )
2017
5
Vocal fold leukoplakia: incidence, management, and prevention. ( 28857841 )
2017
6
Serum metabolomics in oral leukoplakia and oral squamous cell carcinoma. ( 28862226 )
2017
7
Evaluation of Genetic Polymorphisms in Glutathione S-Transferase Theta1, Glutathione S-Transferase Mu1, and Glutathione S-Transferase Mu3 in Oral Leukoplakia and Oral Squamous Cell Carcinoma with Deleterious Habits using Polymerase Chain Reaction. ( 28904918 )
2017
8
Association between oral leukoplakia and risk of upper gastrointestinal cancer death: A follow-up study of the Linxian General Population Trial. ( 28929584 )
2017
9
Quantitative prediction of oral cancer risk in patients with oral leukoplakia. ( 28545021 )
2017
10
Snail and Axin2 expression predict the malignant transformation of oral leukoplakia. ( 28939076 )
2017
11
Treatment outcome of vocal cord leukoplakia by transoral laser microsurgery. ( 27686889 )
2017
12
In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia. ( 28580171 )
2017
13
Comparison of effectiveness of Calendula officinalis extract gel with lycopene gel for treatment of tobacco-induced homogeneous leukoplakia: A randomized clinical trial. ( 28929051 )
2017
14
Diagnosis of Oral Hairy Leukoplakia: The Importance of EBV In Situ Hybridization. ( 28798771 )
2017
15
Leukoplakia of buccal mucosa with transformation into spindle cell carcinoma: A rare case report. ( 28479698 )
2017
16
Genomic profile of oral squamous cell carcinomas with an adjacent leukoplakia or with an erythroleukoplakia that evolved after the treatment of primary tumor: A report of two cases. ( 28901451 )
2017
17
Malignant Transformation in Leukoplakia and Its Associated Factors in Southern Iran: A Hospital Based Experience. ( 28894713 )
2017
18
Malignant transformation of oral leukoplakia in a patient with dyskeratosis congenita. ( 28923296 )
2017
19
Evaluation of Different Laser-Supported Surgical Protocols for the Treatment of Oral Leukoplakia: A Long-Term Follow-Up. ( 28426376 )
2017
20
Nomogram for risk prediction of malignant transformation in oral leukoplakia patients using combined biomarkers. ( 28797449 )
2017
21
Detecting Laryngopharyngeal Reflux by Immunohistochemistry of Pepsin in the Biopsies of Vocal Fold Leukoplakia. ( 28756936 )
2017
22
Interventions for treating oral leukoplakia to prevent oral cancer. ( 28537153 )
2017
23
Evaluation of Total and Lipid Bound Sialic Acid in Serum in Oral Leukoplakia. ( 28511503 )
2017
24
Plasma HPV DNA is detectable in oral leukoplakia patients. ( 28554767 )
2017
25
A comparative evaluation: Oral leukoplakia surgical management using diode laser, CO2 laser, and cryosurgery. ( 28638555 )
2017
26
Expression of Human Papillomavirus DNA and p53 Polymorphisms through Polymerase Chain Reaction in Normal Mucosa and Oral Leukoplakia Individuals with Deleterious Oral Habits. ( 28584747 )
2017
27
Serial in-office laser treatment of vocal fold leukoplakia: Disease control and voice outcomes. ( 28083976 )
2017
28
Cytological study of DNA content and nuclear morphometric analysis for aid in the diagnosis of high-grade dysplasia within oral leukoplakia. ( 28732697 )
2017
29
Chemoprevention of oral cancer in leukoplakia patients: A systematic review and meta-analysis. ( 28924285 )
2017
30
Widefield Endoscopic Mucosal Resection for Treatment of Proximal Esophageal Leukoplakia. ( 28804029 )
2017
31
A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients. ( 28545482 )
2017
32
Factors affecting Clinical Outcomes after Treatment of Oral Leukoplakia with CO2 and Diode Laser. ( 28874640 )
2017
33
Oral hairy leukoplakia arising in a patient with hairy cell leukaemia: the first reported case. ( 28385698 )
2017
34
Prevalence of Carcinomatous Foci in Oral Leukoplakia: A Clinicopathologic Study of 546 Indian Samples. ( 27656569 )
2016
35
Aberrant DKK3 expression in the oral leukoplakia and oral submucous fibrosis: a comparative immunohistochemical study. ( 27349317 )
2016
36
Diode laser: In treatment of recurrent verrucous leukoplakia. ( 27307679 )
2016
37
High-risk oral leukoplakia is associated with aberrant promoter methylation of multiple genes. ( 27255271 )
2016
38
Signal regulatory protein I+ associated with the progression of oral leukoplakia and oral squamous cell carcinoma regulates phenotype switch of macrophages. ( 27793032 )
2016
39
Cancer-associated fibroblasts are an infrequent finding in the microenvironment of proliferative verrucous leukoplakia-associated squamous cell carcinoma. ( 27681951 )
2016
40
Changes in the salivary microbiota of oral leukoplakia and oral cancer. ( 27026576 )
2016
41
Immunohistochemical study of p21 and Bcl-2 in leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma. ( 27849339 )
2016
42
MicroRNAs-208b-3p, 204-5p, 129-2-3p and 3065-5p as predictive markers of oral leukoplakia that progress to cancer. ( 27508095 )
2016
43
A Novel Mutation in the DNA Binding Domain of NFKB is Associated with Speckled Leukoplakia. ( 27510021 )
2016
44
Web-based information on the treatment of oral leukoplakia - quality and readability. ( 27233229 )
2016
45
Role of human papilloma virus in oral leukoplakia. ( 27146781 )
2016
46
A proteomic approach to compare saliva from individuals with and without oral leukoplakia. ( 27478070 )
2016
47
Resolution of vocal fold leukoplakia during erlotinib treatment for lung cancer. ( 26930330 )
2016
48
Phonosurgical resection using submucosal infusion technique for precancerous laryngeal leukoplakia. ( 27107249 )
2016
49
Successful treatment of proliferative verrucous leukoplakia with 5% topical imiquimod. ( 27647537 )
2016
50
Vascular alterations after photodynamic therapy mediated by 5-aminolevulinic acid in oral leukoplakia. ( 28004205 )
2016

Variations for Leukoplakia

Copy number variations for Leukoplakia from CNVD:

7 (show all 16)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 299983 1 197500000 205300000 Gain CAMSAP1L1 Leukoplakia
2 299999 1 222700000 225100000 Gain PARP1 Leukoplakia
3 300051 1 32200000 34400000 Gain KHDRBS1 Leukoplakia
4 300126 10 103000000 104900000 Gain NPM3 Leukoplakia
5 300490 11 70700000 74900000 Gain CHRDL2 Leukoplakia
6 300847 14 23600000 31800000 Gain GMPR2 Leukoplakia
7 300848 14 23600000 31800000 Gain IRF9 Leukoplakia
8 300849 14 23600000 31800000 Gain REC8 Leukoplakia
9 300904 14 90500000 92800000 Copy number BTBD7 Leukoplakia
10 300905 14 90500000 92800000 Gain BTBD7 Leukoplakia
11 303215 2 64000000 70500000 Gain RAB1A Leukoplakia
12 303505 22 30500000 35900000 Gain FBXO7 Leukoplakia
13 303978 5 135400000 139000000 Gain PAIP2 Leukoplakia
14 303979 5 139000000 143100000 Gain HBEGF Leukoplakia
15 304504 7 43300000 46600000 Gain TBRG4 Leukoplakia
16 304704 8 2200000 6200000 Loss CSMD1 Leukoplakia

Expression for Leukoplakia

Search GEO for disease gene expression data for Leukoplakia.

Pathways for Leukoplakia

GO Terms for Leukoplakia

Cellular components related to Leukoplakia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament cytoskeleton GO:0045111 9.33 KRT13 KRT4 KRT8
2 intermediate filament GO:0005882 9.26 KRT1 KRT13 KRT4 KRT8
3 keratin filament GO:0045095 8.92 KRT1 KRT13 KRT4 KRT8

Biological processes related to Leukoplakia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.46 CYP1A1 DKC1 MKI67 PCNA
2 glutathione metabolic process GO:0006749 9.32 GSTM1 GSTT1
3 glutathione derivative biosynthetic process GO:1901687 9.26 GSTM1 GSTT1
4 keratinization GO:0031424 9.26 KRT1 KRT13 KRT4 KRT8
5 cornification GO:0070268 8.92 KRT1 KRT13 KRT4 KRT8

Molecular functions related to Leukoplakia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 glutathione transferase activity GO:0004364 8.96 GSTM1 GSTT1
2 structural molecule activity GO:0005198 8.92 KRT1 KRT13 KRT4 KRT8

Sources for Leukoplakia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....